Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2013

View Archived Issues

Novel aminoglycoside antibiotic shows anti-MRSA activity with reduced nephrotoxicity

CETP inhibitors for the treatment of atherosclerosis

Smallpox vaccine CJ-50300 safe in phase III trial

Novan compares activity of Nitricil compounds against Staphylococcus aureus

Acacia Pharma initiates phase III studies of APD-421 for PONV

Regado Biosciences begins phase III trial of pegnivacogin/anivamersen

PeptiDream licenses PDPS technology to Bristol-Myers Squibb

AGE receptors identified in human osteoarthritic cartilage

Agenus reports follow-on phase II data for brain cancer vaccine

Third review also recommends PreSERVE AMI study continuation

Repros Therapeutics reports Androxal study data

BioCryst awarded NIAID contract to combat Marburg virus hemorrhagic fever

Eslicarbazepine acetate meets primary endpoint in two phase III epilepsy studies

GW Pharmaceuticals begins phase I study of cannabinoid GWP-42006 for epilepsy

Profectus BioSciences begins phase I trial of HIV plasmid DNA vaccine

H3 Biomedicine and Selvita establish strategic collaboration in oncology

Compugen reports data on immune checkpoint protein CGEN-15049

Rottapharm patents novel orexin OX1 receptor antagonists

FORMA Therapeutics and Genentech disclose Nampt inhibitors

PIQUR Therapeutics plans phase I study of PQR-309

Takeda designs series of MetAP 2 inhibitors

Allergan synthesizes series of chemokine CCR2 receptor antagonists

ChemoCentryx regains rights to vercirnon from GlaxoSmithKline

Mitsubishi Tanabe Pharma acquires Medicago

CE mark granted to Abbott's FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...